Under this M-CRADA, NCI will assess Serenex’s novel, small molecule, orally bioavailable Hsp90 inhibitor SNX-5422 as a potential therapeutic for non-small cell lung cancer.
Richard Kent, president and CEO of Serenex, said: “This important collaboration with the NCI further validates the potential of our Hsp90 Product Platform. We look forward to collaborating with NIC to generate additional data to support initiating clinical trials in patients with lung cancer.”